New treatment options for hypertension during acute ischemic or hemorrhagic stroke


Opinion statement

Widespread reluctance to treat hypertension during acute stroke is based on historical accounts of unfavorable outcomes of treatment that were badly done: therapies that cannot be controlled, such as sublingual nifedipine, oral or intramuscular antihypertensive drugs may drop blood pressure precipitously, leading to worsening of ischemia. Case fatality in stroke obeys a U-shaped relationship: blood pressures that are either too low or too high are associated with worse outcomes both in ischemic stroke and in intracerebral hemorrhage. Very high blood pressures should be lowered in acute stroke, and there are some circumstances in which high blood pressure must be treated despite the presence of stroke. To avoid worsening of ischemia by reduction in cerebral blood flow, it is necessary to treat high blood pressure in acute stroke with drugs that can be controlled; this usually means giving drugs by intravenous infusion; however, there is recent evidence that transdermal administration of nitrates, which can be removed if pressure is too low, is a convenient alternative that does not reduce cerebral blood flow in acute stroke.

References and Recommended Reading

  1. 1.
    Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA: Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002, 33:1315–1320.PubMedCrossRefGoogle Scholar
  2. 2.
    Okumura K, Ohya Y, Maehara A, et al.: Effects of blood pressure levels on case fatality after acute stroke. J Hypertens 2005, 23:1217–223.PubMedCrossRefGoogle Scholar
  3. 3.
    Dandapani BK, Suzuki S, Kelley RE, et al.: Relation between blood pressure and outcome in intracerebral hemorrhage. Stroke 1995, 26:21–24.PubMedGoogle Scholar
  4. 4.
    Adams H, Adams R, Del ZG, Goldstein LB: Guidelines for the early management of patients with ischemic stroke: 2005 guidelines up date a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 2005, 36:916–923.PubMedCrossRefGoogle Scholar
  5. 5.
    Yatsu FM, Zivin J: Hypertension in acute ischemic strokes. Not to treat. Arch Neurol 1985, 42:999–1000.PubMedGoogle Scholar
  6. 6.
    Spence JD, Del Maestro RF: Hypertension in acute ischemic strokes. Treat. Arch Neurol 1985, 42:1000–1002.PubMedGoogle Scholar
  7. 7.
    Bath P, Chalmers J, Powers W, et al.: International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. J Hypertens 2003, 21:665–672.PubMedCrossRefGoogle Scholar
  8. 8.
    Chalmers J: Blood pressure and stroke: a continuing debate. J Hypertens 2006, 24:1249–1251.PubMedCrossRefGoogle Scholar
  9. 9.
    Willmot M, Ghadami A, Whysall B, et al.: Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension 2006, 47:1209–1215.PubMedCrossRefGoogle Scholar
  10. 10.
    Bath PM: Major ongoing stroke trials. Efficacy of Nitric Oxide in Stroke (ENOS) trial [abstract]. Stroke 2001, 32:2450–2451.Google Scholar
  11. 11.
    Doba N, Reis DJ: Acute fulminating neurogenic hypertension produced by brainstem lesions in the rat. Circ Res 1973, 32:584–593.PubMedGoogle Scholar
  12. 12.
    Nathan MA, Reis DJ: Fulminating arterial hypertension with pulmonary edema from release of adrenomedullary catecholamines after lesions of the anterior hypothalamus in the rat. Circ Res 1975, 37:226–235.PubMedGoogle Scholar
  13. 13.
    Mazey RM, Kotchen TA, Ernst CB: A syndrome resembling pheochromocytom a following a stroke. Report of a case. JAMA 1974, 230:575–577.PubMedCrossRefGoogle Scholar
  14. 14.
    Willmot M, Leonardi-Bee J, Bath PM: High blood pressure in acute stroke and subsequent outcome: a systematic review. Hypertension 2004, 43:18–24.PubMedCrossRefGoogle Scholar
  15. 15.
    Sprigg N, Gray LJ, Bath PM, et al.: Relationship between outcome and baseline blood pressure and other haemodynamic measures in acute ischaemic stroke: data from the TAIST trial. J Hypertens 2006, 24:1413–1417.PubMedCrossRefGoogle Scholar
  16. 16.
    Halsey JH Jr, O’Brien MD: Role of hypertension in pathogenesis of cerebral infarction edema. Adv Neurol 1980, 28:317–321.PubMedGoogle Scholar
  17. 17.
    Hayakawa T, Waltz AG, Jacobson RL: Hypertension and acute focal cerebral ischemia. Infarction and edem a after occlusion of a middle cerebral artery in cats. Stroke 1979, 10:263–267.PubMedGoogle Scholar
  18. 18.
    Karki A, Westergren I, Widner H, et al.: Tirilazad reduces brain edem a after middle cerebral artery ligation in hypertensive rats. Acta Neurochir Suppl (Wien) 1994, 60:310–313.Google Scholar
  19. 19.
    Paulson OB, Lassen NA, Skinhoj E: Regional cerebral blood flow in apoplexy without arterial occlusion. Neurology 1970, 20:125–138.PubMedGoogle Scholar
  20. 20.
    Strandgaard S: Autoregulation of cerebral blood flow in hypertensive patients. The modifying influence of prolonged antihypertensive treatment on the tolerance to acute, drug-induced hypotension. Circulation 1976, 53:720–727.PubMedGoogle Scholar
  21. 21.
    van HJ, Burggraaf K, Danhof M, et al.: Negligible sublingual absorption of nifedipine. Lancet 1987, 2:1363–1365.Google Scholar
  22. 22.
    Schrader J, Luders S, Kulschewski A, et al.: The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003, 34:1699–1703.PubMedCrossRefGoogle Scholar
  23. 23.
    Hackam DG, Thain LM, Abassakoor A, et al.: Trapped renal arteries: functional renal artery stenosis due to occlusion of the aorta in the arch and below the kidneys. Can J Cardiol 2001, 17:587–592.PubMedGoogle Scholar
  24. 24.
    Spence JD: Management of resistant hypertension in patients with carotid stenosis: high prevalence of renovascular hypertension. Cerebrovasc Dis 2000, 10:249–254.PubMedCrossRefGoogle Scholar
  25. 25.
    Spence JD: Individualized therapy for hypertension. Hypertension 2006, 47:e11.PubMedCrossRefGoogle Scholar
  26. 26.
    Spence JD: Physiologic tailoring of therapy for resistant hypertension: 20 years’ experience with stimulated renin profiling. Am J Hypertens 1999, 12(11 Pt 1):1077–1083.PubMedGoogle Scholar
  27. 27.
    Biglieri EG, Kater CE, Arteaga EE: Primary aldosteronism is comprised of primary adrenal hyperplasia and adenoma. J Hypertens Suppl 1984, 2:S259–S261.PubMedGoogle Scholar
  28. 28.
    Baker EH, Duggal A, Dong Y, et al.: Amiloride, a specific drug for hypertension in black people with T594M variant? Hypertension 2002, 40:13–17.PubMedCrossRefGoogle Scholar
  29. 29.
    Wallach L, Nyarai I, Dawson KG: Stimulated renin: a screening test for hypertension. Ann Intern Med 1975, 82:27–34.PubMedGoogle Scholar
  30. 30.
    Butterworth RJ, Cluckie A, Jackson SH, et al.: Pathophysiological assessment of nitric oxide (given as so dium nitroprusside) in acute ischaemic stroke. Cerebrovasc Dis 1998, 8:158–165.PubMedCrossRefGoogle Scholar
  31. 31.
    Rindone JP, Sloane EP: Cyanide toxicity from sodium nitroprusside: risks and management. Ann Pharmacother 1992, 26:515–519.PubMedGoogle Scholar
  32. 32.
    Alaniz C, Watts B: Monitoring cyanide toxicity in patients receiving nitroprusside therapy. Ann Pharmacother 2005, 39:388–389.PubMedCrossRefGoogle Scholar
  33. 33.
    Gogbashian A: Nitroprusside in critically ill patients with aortic stenosis. N Engl J Med 2003, 349:811–813.PubMedCrossRefGoogle Scholar
  34. 34.
    Khot UN, Novaro GM, Popovic ZB, et al.: Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 2003, 348:1756–1763.PubMedCrossRefGoogle Scholar
  35. 35.
    Sinaiko AR: Hypertension in children. N Engl J Med 1996, 335:1968–1973.PubMedCrossRefGoogle Scholar
  36. 36.
    Spence JD: Treating hypertension in acute stroke: a better arrow for the quiver. Hypertension 2006, 47:1051.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Stroke Prevention & Atherosclerosis Research CentreRobarts Research InstituteLondonCanada

Personalised recommendations